SwePub - sökning: WFRF:(Gaillat J)

Numrering	Referens	Omslagsbild	Hitta
1.	Ament, A, et al. (författare) Cost-Effectiveness of Pneumococcal Vaccination of Older People: A Study in 5 Western European Countries 2000 Ingår i: Clinical infectious diseases. - : The University of Chicago Press. - 1537-6591 .- 1058-4838. ; 31:2, s. 444-450 Tidskriftsartikel (refereegranskat)abstract Pneumococcal vaccination of older persons is thought to be cost-effective in preventing pneumococcal pneumonia, but evidence of clinical protection is uncertain. Because there is better evidence of vaccination effectiveness against invasive pneumococcal disease, we determined the cost-effectiveness of pneumococcal vaccination of persons aged ≥65 years in preventing hospital admission for both invasive pneumococcal disease and pneumococcal pneumonia in 5 western European countries. In the base case analyses, the cost-effectiveness ratios for preventing invasive disease varied from ∼11,000 to ∼33,000 European currency units (ecu) per quality-adjusted life year (QALY). Assuming a common incidence (50 cases per 100,000) and mortality rate (20%-40%) for invasive disease, the cost-effectiveness ratios were <12,000 ecu per QALY in all 5 countries. For preventing pneumococcal pneumonia, vaccinating all elderly persons would be highly cost-effective to cost saving. Public health authorities should consider policies for encouraging pneumococcal vaccination for all persons aged ≥65 years.

Ament, A, et al. (författare)
Cost-Effectiveness of Pneumococcal Vaccination of Older People: A Study in 5 Western European Countries
2000
Ingår i: Clinical infectious diseases. - : The University of Chicago Press. - 1537-6591 .- 1058-4838. ; 31:2, s. 444-450
Tidskriftsartikel (refereegranskat)abstract
- Pneumococcal vaccination of older persons is thought to be cost-effective in preventing pneumococcal pneumonia, but evidence of clinical protection is uncertain. Because there is better evidence of vaccination effectiveness against invasive pneumococcal disease, we determined the cost-effectiveness of pneumococcal vaccination of persons aged ≥65 years in preventing hospital admission for both invasive pneumococcal disease and pneumococcal pneumonia in 5 western European countries. In the base case analyses, the cost-effectiveness ratios for preventing invasive disease varied from ∼11,000 to ∼33,000 European currency units (ecu) per quality-adjusted life year (QALY). Assuming a common incidence (50 cases per 100,000) and mortality rate (20%-40%) for invasive disease, the cost-effectiveness ratios were <12,000 ecu per QALY in all 5 countries. For preventing pneumococcal pneumonia, vaccinating all elderly persons would be highly cost-effective to cost saving. Public health authorities should consider policies for encouraging pneumococcal vaccination for all persons aged ≥65 years.

Träfflista för sökning "WFRF:(Gaillat J) "